Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

نویسندگان

  • Francesco Passamonti
  • Francisco Cervantes
  • Alessandro Maria Vannucchi
  • Enrica Morra
  • Elisa Rumi
  • Mario Cazzola
  • Ayalew Tefferi
چکیده

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) with a high propensity to develop acute myeloid leukemia, named at this stage blast phase (BP) of PMF.1 Oncogenic JAK2 signaling is an important event in MPN, but transformation process into BP, although not completely understood, often involves additional genomic lesions.2 Several models have been developed to predict survival in PMF.3-5 Concerning BP occurrence, leukocyte count more than 30 109/L,5 blast cell count more than 10%,6 platelet count below 50 109/L,6 red blood cell transfusion dependency,7 selected cytogenetic abnormalities,6,8 low JAK2(V617F) allele burden9 have been reported to shorten BP-free survival. The International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) has recently developed a time-dependent prognostic model, named Dynamic International Prognostic Scoring System (DIPSS) to predict survival anytime in patients with PMF.10 This model includes age older than 65 years, hemoglobin level lower than 10 g/dL, white blood cell count more than 25 109/L, peripheral blood blasts equal to or higher than 1%, and constitutional symptoms. In this study, we investigated whether DIPSS may also predict the occurrence of BP. The study was approved by the Institutional Review Board of each participating center, and the procedures followed were in accordance with the Declaration of Helsinki. On behalf of IWG-MRT, we surveyed the large-scale international database of 525 regularly followed patients with PMF, which allowed the definition of DIPSS.10 Blast phase was defined when a threshold of 20% peripheral blast cells was achieved during follow-up. Among 525 patients, 70 (13%) developed BP after a median time of 2.8 years (range, .2-14.5). Median age was 68 years (range, 31-90 years), 58 (83%) patients were male, and 56 (80%) received cytotoxic agents during chronic phase. The incidence of BP was 0.3 (95% confidence interval [CI]: 0.04-1.2) 100 patient/years in low-risk category, 0.7 (95% CI: 0.2-1.7) 100 patient/years in intermediate-1, 2.6 (95% CI: 1.4-4.4) 100 patient/years in intermediate-2, and 8.6 (95% CI: 6.4-11.4) 100 patient/years in high risk. We analyzed the categorical DIPSS score as a time-dependent covariate in a Cox survival regression model with BP as outcome (Figure 1). Overall, the Gehan Wilcoxon test showed that DIPSS stratified PMF patients for BP risk (P .001). The increase in risk when changing risk category was further estimated as a hazard ratio (HR). The estimated HRs were: 2 (95% CI: 0.4-11.3; P .4) if the risk category shifted from low to intermediate-1, 3.8 (95% CI: 1.2-11.4; P .019) from intermediate-1 to intermediate-2, and 3.2 (95% CI: 1.8-5.8; P .001) from intermediate-2 to high. Comparing higher risk categories to low-risk category, HR was 7.8 (95% CI: 1.8-34.2; P .007) for intermediate-2 and 24.9 (95% CI: 6-102.3; P .001) for high risk. The study shows that modification of the DIPSS during follow-up of PMF patients may also predict different risks of BP. Patients belonging to the higher risk categories have a notable 7.8-fold and 24.9-fold higher risk of developing BP comparing to those who continue to fit in low-risk category. As BP evolution implies a dismal outcome,1 this observation recommends to approach patients with higher DIPSS categories for intensive or investigative treatments.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

Studies by the International Working Group showed that the prognosis of myelofibrosis patients is predicted by the Dynamic International Prognostic Scoring System (DIPSS) risk categorization, which includes patient age, constitutional symptoms, hemoglobin, leukocyte count, and circulating blasts. We evaluated the prognostic usefulness of the DIPSS in 170 patients with myelofibrosis, 12 to 78 ye...

متن کامل

Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.

DISEASE OVERVIEW Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by stem cell-derived clonal myeloproliferation, abnormal cytokine expression, bone marrow fibrosis, anemia, splenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. DIAGNOSIS DIAGNOSIS is based on bone marrow morphology. The pres...

متن کامل

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7-8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presen...

متن کامل

Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic neoplasms, characterized by dysplastic findings with variable degree of bone marrow failure and proliferation of blast cells.1 It is the most common neoplastic disease of the bone marrow, with an estimated incidence of 1.3–5 per 100,000 people annually, and reaching 36 per 100,000 in patients aged 80 years or over...

متن کامل

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

Anemia is a cardinal manifestation of primary myelofibrosis (PMF) and constitutes a negative prognostic factor, being an independent risk factor for survival both in the international prognostic score system (IPSS) and dynamic IPSS (DIPSS)-plus. Anemia in myelofibrosis is also inversely correlated with patient-reported quality of life. Between 35 and 54% of patients with PMF are anemic at diagn...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Blood

دوره 116 15  شماره 

صفحات  -

تاریخ انتشار 2010